Romosozumab in Postmenopausal Women with Low Bone Mineral Density
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. METHODS: In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator--oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 μg daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. RESULTS: All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. CONCLUSIONS: In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the simultaneous, acute increase in P1NP and reduction in CTx that we observed in the T3 group is qualitatively identical (but smaller in magnitude) to the effects of sclerostin inhibition on bone markers in humans22, and arguably pathognomonic of the consequences of sclerostin inhibition on bone.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
In the citing paper
“the time course of changes in bone formation we observed over 20 weeks of intermittent D + Q treatment in the T3 group is virtually identical (albeit smaller in magnitude) to that observed following treatment with the FDA-approved sclerostin inhibitor, romosozumab, where serum P1NP increased rapidly over the first 1–4 weeks following dosing and then returned to baseline by 24 weeks22.”
From Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial (2024) · cites this paper as [22]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Cited by
Items 601–700 of 1,000
Romosozumab, clinical trials, and real-world care of patients with osteoporosis
Lewiecki, E. M. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.196 · Cited by 18
New treatments for osteoporosis
(1990) · The Lancet · doi:10.1016/0140-6736(90)92635-u · Cited by 21
The Dual Role and Therapeutic Implications of the Wnt/β-Catenin Pathway in Diabetic Kidney Disease
Adeerjiang, Y., Gan, X.-X., Li, W., Li, Q., Jiang, Y., Xia Shuang, Z. H. U., Hu, C.-M., Wang, P., & Jiang, S. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s524138 · Cited by 17
Raftery, J. P., Hanney, S. R., Greenhalgh, T., Glover, M. J., & Blatch-Jones, A. (2016) · Cited by 17
Mesenchymal stem/stromal cells-derived exosomes for osteoporosis treatment
Huo, K., Yang, T., Zhang, W., & Shao, J. (2023) · World Journal of Stem Cells · doi:10.4252/wjsc.v15.i3.83 · Cited by 19
The roles of hepatokine and osteokine in liver-bone crosstalk: Advance in basic and clinical aspects
Li, Z., Wen, X., Li, N., Zhong, C., Chen, L., Zhang, F., Zhang, G., Lü, A., & Liu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1149233 · Cited by 21
Martin, T. J., & Seeman, E. (2023) · Neurospine · doi:10.14245/ns.2346966.483 · Cited by 19
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?
Anastasilakis, A. D., Yavropoulou, M. P., Palermo, A., Makras, P., Paccou, J., Tabacco, G., Naciu, A. M., & Tsourdi, E. A. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae076 · Cited by 17
Kawazoe, M., Kaneko, K., Masuoka, S., Yamada, S., Yamada, Z., Muraoka, S., Furukawa, K., Sato, H., Watanabe, E., Koshiba, K., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae810 · Cited by 20
Mariscal, G., Núñez, J. H., Bhatia, S., Barrios, C., & Domenech-Fernández, P. (2020) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2019.0049 · Cited by 18
Prideaux, M., Wright, C. S., Noonan, M. L., Yi, X., Clinkenbeard, E. L., Mével, E., Wheeler, J. A., Byers, S., Wijenayaka, A. R., Gronthos, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02060-1 · Cited by 22
Osteoarthritis: Insights Offered by the Study of Bone Mass Genetics
Hartley, A. E., Gregson, C. L., Paternoster, L., & Tobias, J. H. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-021-00655-1 · Cited by 18
Hagino, H., Tanaka, K., Silverman, S. L., McClung, M. R., Gandra, S., Charokopou, M., Adachi, K., Johnson, B., & Stollenwerk, B. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05927-1 · Cited by 20
Self-citationThe use of bone-modifying agents in multiple myeloma
Hussain, M., Khan, F., & Hadidi, S. A. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100999 · Cited by 20
Treatment with anti‐Sclerostin antibody to stimulate mandibular bone formation
Tamplen, M. L., Fowler, T. W., Markey, J., Knott, P. D., Suva, L. J., & Alliston, T. N. (2018) · Head & Neck · doi:10.1002/hed.25128 · Cited by 18
Möckel, L., Bartneck, M., & Möckel, C. (2020) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2020.02.003 · Cited by 17
Simfia, I., Schiavi, J., & McNamara, L. M. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112005 · Cited by 18
New treatments of osteoporosis
Langdahl, B. L. (2015) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2015.07.007 · Cited by 17
Self-citationImproving Bone Health by Optimizing the Anabolic Action of Wnt Inhibitor Multitargeting
Choi, R. B., Bullock, W. A., Hoggatt, A. M., Loots, G. G., Genetos, D. C., & Robling, A. G. (2021) · JBMR Plus · doi:10.1002/jbm4.10462 · Cited by 18
Asperuloside Prevents Peri-Implantitis via Suppression of NF-κB and ERK1/2 on Rats
Wang, X., Chen, X., Zhang, Z., Chen, J., Ge, Z., Huang, S., Wei, H., & Li, D. (2022) · Pharmaceuticals · doi:10.3390/ph15081027 · Cited by 17
Miyauchi, A., Hamaya, E., Shimauchi, J., Yoshinaga, Y., & Nishi, K. (2023) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-023-01477-0 · Cited by 17
Migliorini, F., Maffulli, N., Colarossi, G., Filippelli, A., Memminger, M. K., & Conti, V. (2025) · European journal of medical research · doi:10.1186/s40001-025-02412-x · Cited by 19
Rauner, M., Stein, N., & Hofbauer, L. C. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0520-7_1 · Cited by 19
Update on osteoporosis from the 2014 Santa Fe Bone symposium
Lewiecki, E. M., Bilezikian, J. P., Binkley, N., Hans, D. B., Krueger, D. C., Miller, P. D., Oates, M. K., & Shane, E. J. (2015) · Endocrine Research · doi:10.3109/07435800.2015.1005746 · Cited by 16
Janeczek, A. A., Tare, R. S., Scarpa, E., Moreno-Jiménez, I., Rowland, C. A., Jenner, D. C., Newman, T. A., Oreffo, R. O. C., & Evans, N. D. (2015) · Stem Cells · doi:10.1002/stem.2241 · Cited by 16
Zhou, P.-R., Xu, X., Zhang, Z., Liao, E.-Y., Chen, D., Liu, J., Wu, W., Jiang, Y., Wang, O., Xia, W., et al. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.76 · Cited by 16
Bone Regeneration: Current Status and Future Prospects
Ghanbari, H., & Vakili‐Ghartavol, R. (2016) · InTech eBooks · doi:10.5772/63912 · Cited by 22
Clinical utility of anti-sclerostin antibodies
McClung, M. R. (2017) · Bone · doi:10.1016/j.bone.2016.12.012 · Cited by 17
Self-citationMetcalf, L. M., Aspray, T., & McCloskey, E. V. (2017) · Bone · doi:10.1016/j.bone.2017.03.007 · Cited by 17
Positioning novel biologicals in CKD-mineral and bone disorders
Tartaglione, L., Pasquali, M., Rotondi, S., Muci, M. L., Covic, A. C., & Mazzaferro, S. (2017) · Journal of Nephrology · doi:10.1007/s40620-017-0410-1 · Cited by 19
Bone Cell Communication Factors Provide a New Therapeutic Strategy for Osteoporosis
Kim, J. H., & Kim, N. (2020) · Chonnam Medical Journal · doi:10.4068/cmj.2020.56.2.94 · Cited by 18
Chlebek, C., Moore, J. A., Ross, F. P., & van der Meulen, M. C. H. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4686 · Cited by 19
Sardar, A., Ansari, A., Gupta, S., Sinha, S., Pandey, S., Rai, D., Kumar, M., Bhatta, R. S., Trivedi, R., & Sashidhara, K. V. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114813 · Cited by 16
TIEG and estrogen modulate SOST expression in the murine skeleton
Subramaniam, M., Pitel, K. S., Bruinsma, E. S., Monroe, D. G., & Hawse, J. R. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26211 · Cited by 16
Williams, D. K., Parham, S. G., Schryver, E. M., Akel, N. S., Shelton, R. S., Webber, J. S., Swain, F. L., Schmidt, J., Suva, L. J., & Gaddy, D. (2017) · JBMR Plus · doi:10.1002/jbm4.10025 · Cited by 16
Li, S., Huang, B., Jiang, B., Gu, M., Yang, X., & Yin, Y. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00159 · Cited by 16
Genome-Wide Mapping and Interrogation of the Nmp4 Antianabolic Bone Axis
Childress, P., Stayrook, K. R., Alvarez, M. B., Wang, Z. P., Shao, Y., Hernandez-Buquer, S., Mack, J. K., Grese, Z. R., He, Y., Horan, D. J., et al. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1406 · Cited by 17
Chiu, S.-H., Wu, W., Yao, T.-K., Peng, C.-H., & Yeh, K. (2024) · Biomedicines · doi:10.3390/biomedicines12122880 · Cited by 17
Wei, F., Gao, Q.-Y., Zhu, K.-L., Wei, H., Du, M., Yang, F., Gao, H.-R., Li, T., Qian, J., & Zhou, C.-P. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11880 · Cited by 15
Noh, M., Che, X., Jin, X., Lee, D.-K., Kim, H., Park, D. R., Lee, S. Y., Lee, H., Gardella, T. J., Choi, J., et al. (2025) · eLife · doi:10.7554/elife.97579.5 · Cited by 11
Anti-sclerostin – is there an indication?
Larsson, S. (2016) · Injury · doi:10.1016/s0020-1383(16)30008-0 · Cited by 18
Hiraga, T. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1142972 · Cited by 15
Morse, A., McDonald, M. M., Schindeler, A., Peacock, L., Mikulec, K., Cheng, T. L., Liu, M., Ke, H. Z., & Little, D. G. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0275-2 · Cited by 16
Advances in osteoporosis from 1970 to 2018
Gallagher, J. C. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001263 · Cited by 17
Sclerostin within the chronic kidney disease spectrum
Bouquegneau, A., Evenepoel, P., Paquot, F., Malaise, O., Cavalier, E., & Delanaye, P. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.12.008 · Cited by 18
Monitoring and maintaining bone health in patients with Turner syndrome
Chiarito, M., Brunetti, G., D’Amato, G., & Faienza, M. F. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1834846 · Cited by 20
Poutoglidou, F., Samoladas, E., Raikos, Ν., & Kouvelas, D. (2021) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2021.11.005 · Cited by 16
Improvement of Mineral and Bone Disorders After Renal Transplantation
Ferreira, A. C., Mendes, M., Silva, C., Cotovio, P., Aires, I., Navarro, D., Caeiro, F., Ramos, R., Salvador, R., Correia, B., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004099 · Cited by 15
Brent, M. B., Brüel, A., & Thomsen, J. S. (2022) · Bone · doi:10.1016/j.bone.2022.116417 · Cited by 15
Therapeutic approaches to activate the canonical Wnt pathway for bone regeneration
Nelson, A. L., Fontana, G., Miclau, E., Rongstad, M., Murphy, W. L., Huard, J., Ehrhart, N. P., & Bahney, C. S. (2022) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3349 · Cited by 18
Wagner, J. M., Reinkemeier, F., Dadras, M., Wallner, C., Huber, J., Sogorski, A., Sacher, M., Schmidt, S. V., Drysch, M., Dittfeld, S., et al. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01924-9 · Cited by 15
Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics
Eriksen, E. F., & Brown, J. P. (2016) · Bone · doi:10.1016/j.bone.2016.02.009 · Cited by 15
Self-citationWhat is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?
Reid, I. R. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2160445 · Cited by 15
Kleber, M., Ntanasis‐Stathopoulos, I., Dimopoulos, M. A., & Terpos, E. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1640115 · Cited by 16
Dong, H., Liu, R., Zou, K., Jin, Z., Kang, J., Zhang, Y., Zhang, X., Sun, Z., Yu, G., Huang, N., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4800 · Cited by 15
Lane, N. E., Betah, D., Deignan, C., Oates, M. K., Wang, Z., Timoshanko, J., Khan, A. A., & Binkley, N. (2023) · ACR Open Rheumatology · doi:10.1002/acr2.11619 · Cited by 17
A practical approach for anabolic treatment of bone fragility with romosozumab
Cianferotti, L., Cipriani, C., Palermo, A., Viapiana, O., Zavatta, G., & Mazziotti, G. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02395-2 · Cited by 14
Yukishima, T., Ebina, K., Etani, Y., Noguchi, T., Ohmura, S., Nakata, K., Okada, S., & Kobayakawa, T. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07386-4 · Cited by 14
Miyamoto, T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041138 · Cited by 15
Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases
Hetta, H. F., Elsaghir, A., Sijercic, V. C., Ahmed, A. K., Gad, S. A., Zeleke, M. S., Alanazi, F. E., & Ramadan, Y. N. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70189 · Cited by 15
Exploiting the WNT Signaling Pathway for Clinical Purposes
Johnson, M. L., & Recker, R. R. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0357-0 · Cited by 14
Update on the Comprehensive Approach to Fragility Fractures
Cohn, M. R., Gianakos, A. L., Grueter, K., Rosen, N. S., Cong, T., & Lane, J. M. (2018) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001244 · Cited by 14
Henssler, L., Kerschbaum, M., Mukashevich, M. Z., Rupp, M., & Alt, V. (2021) · Injury · doi:10.1016/j.injury.2021.04.068 · Cited by 14
Loundagin, L. L., & Cooper, D. (2022) · European Cells and Materials · doi:10.22203/ecm.v043a15 · Cited by 17
Effects of Drugs and Chemotherapeutic Agents on Dental Implant Osseointegration: A Narrative Review
Mohammadi, A., Dehkordi, N. R., Mahmoudi, S., Rafeie, N., Sabri, H., Valizadeh, M., Poorsoleiman, T., Jafari, A., Mokhtari, A., Khanjarani, A., et al. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220607114559 · Cited by 19
McClung, M. R., Betah, D., Deignan, C., Shi, Y., Timoshanko, J., & Cosman, F. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.06.011 · Cited by 14
Self-citationAnti-sclerostin antibodies: a new frontier in fragility fractures treatment
Iolascon, G., Liguori, S., Paoletta, M., Toro, G., & Moretti, A. (2023) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x231197094 · Cited by 15
Aneuploidy and Skeletal Health
Kamalakar, A., Harris, J. R., McKelvey, K. D., & Suva, L. J. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0221-4 · Cited by 14
A contemporary therapeutic approach to bone disease in beta-thalassemia - a review
Stefanopoulos, D., Παπαϊωάννου, Ν., Papavassiliou, A. G., Mastorakos, G. P., Vryonidou, A., Michou, A., Dontas, I. A., Lyritis, G. P., Kassi, E. N., & Tournis, S. (2018) · Journal of Frailty Sarcopenia and Falls · doi:10.22540/jfsf-03-013 · Cited by 16
Ramchand, S. K., & Seeman, E. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_354 · Cited by 18
Bone Turnover Markers: A Clinical Review
Guañabens, N., Peris, P., & Monegal, A. (2015) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-015-9185-x · Cited by 15
Treatment of Osteoporosis in Patients with Chronic Kidney Disease
Laurent, M. R., Dupont, J., Lemahieu, W. P. D., Jamar, S., Mellaerts, B., Dejaeger, M., Gielen, E., & Evenepoel, P. (2025) · Current Osteoporosis Reports · doi:10.1007/s11914-025-00919-0 · Cited by 14
Management of postmenopausal osteoporosis
Reid, I. R., & Bolland, M. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag006 · Cited by 15
Emerging treatment approaches for myeloma-related bone disease
Gavriatopoulou, M., Dimopoulos, M. A., Kastritis, E., & Terpos, E. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1283213 · Cited by 13
Mok, C. C., Chan, K. L., Tse, S. M., Chen, S. P. L., Tan, K. C. B., & Ma, W. H. (2024) · Journal of Internal Medicine · doi:10.1111/joim.20017 · Cited by 15
Sclerostin as a new target of diabetes-induced osteoporosis
Lǐ, Y., Luo, Y., Huang, D., & Peng, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1491066 · Cited by 16
Asamiya, Y., Yajima, A., Shimizu, S., Otsubo, S., Tsuchiya, K., & Nitta, K. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2934-8 · Cited by 16
Value of rare low bone mass diseases for osteoporosis genetics
Costantini, A., & Mäkitie, O. (2016) · BoneKEy Reports · doi:10.1038/bonekey.2015.143 · Cited by 14
Maillard, S., Sicard, L., Andrique, C., Torrens, C., Lesieur, J., Baroukh, B., Coradin, T., Poliard, A., Slimani, L., & Chaussain, C. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.11.046 · Cited by 14
Tratamiento secuencial en osteoporosis. Nuevas tendencias
Casado, E., & Neyro, J. L. (2021) · Revista de Osteoporosis y Metabolismo Mineral · doi:10.4321/s1889-836x2021000400002 · Cited by 13
Park, D., Kim, S. E., Shin, H., Seo, J., Joo, J. K., Kim, C., Lee, S. H., & Park, J. (2023) · Neurospine · doi:10.14245/ns.2347030.515 · Cited by 11
Sclerosing Bone Dysplasias: Leads Toward Novel Osteoporosis Treatments
Fijałkowski, I., Boudin, E., Mortier, G. R., & Hul, W. V. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-014-0220-5 · Cited by 13
de Paula, F. J. A., Black, D. M., & Rosen, C. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00029-0 · Cited by 20
SECOT-GEIOS guidelines in osteoporosis and fragility fracture. An update
Etxebarría-Foronda, Í., Caeiro-Rey, J. R., Larrainzar‐Garijo, R., Vaquero-Cervino, E., Roca-Ruiz, L., Mesa-Ramos, M., Pérez, J. M., Carpintero-Benítez, P., Cebrián, A. F., & Gil-Garay, E. (2015) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recote.2015.09.008 · Cited by 20
Bone-targeted agents in multiple myeloma
Nishida, H. (2018) · Hematology Reports · doi:10.4081/hr.2018.7401 · Cited by 15
Tsartsalis, A. N., Lambrou, G. Ι., Tsartsalis, D. N., Papassotiriou, I., Vlachou, E. D., Terpos, E., Chrousos, G. P., Kanaka‐Gantenbein, C., & Kattamis, A. (2019) · Current Molecular Medicine · doi:10.2174/1566524019666190314114447 · Cited by 14
New management options for osteoporosis with emphasis on SERMs
McClung, M. R. (2015) · Climacteric · doi:10.3109/13697137.2015.1104010 · Cited by 14
Self-citationMurray, S. S., Wang, J. C., Duarte, M. E. L., Zhao, K., Tian, H., Francis, T., & Murray, E. J. B. (2015) · PubMed · doi:10.14670/hh-30.531 · Cited by 13
Iaquinto, G., Sorrentini, I., Petillo, F. E., & Berardesca, G. (1994) · PubMed · Cited by 13
Romosozumab: from basic to clinical aspects
Minisola, S. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.920815 · Cited by 14
Kim, S. P., Seward, A. H., Garcia-Diaz, J. G., Alekos, N. S., Gould, N. R., Aja, S. M., Stains, J. P., Wolfgang, M. J., & Riddle, R. C. (2023) · iScience · doi:10.1016/j.isci.2023.106999 · Cited by 17
The Role of Bone Mineral Density in a Successful Lumbar Interbody Fusion: A Narrative Review
Bekas, K., & Zafeiris, C. (2024) · Cureus · doi:10.7759/cureus.54727 · Cited by 12
Wells, G. A., Hsieh, S., Peterson, J., Zheng, C., Kelly, S., Shea, B., & Tugwell, P. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001155.pub3 · Cited by 16
Application of anti-Sclerostin therapy in non-osteoporosis disease models
Jacobsen, C. M. (2016) · Bone · doi:10.1016/j.bone.2016.10.018 · Cited by 16
Wang, F., Wu, R., Lain, W.-S., Tsai, T.-C., Chen, Y.-S., Sun, Y., Ke, H.-J., Li, J.-C., Hwang, J., & Ko, J. (2018) · Bone · doi:10.1016/j.bone.2018.04.007 · Cited by 12
Hoffmann, G. F., Mundlos, C., Dötsch, J., & Hebestreit, H. U. (2020) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-020-00978-w · Cited by 13
Targeting the Wnt signaling pathway for breast cancer bone metastasis therapy
Cui, J., Chen, H., Zhang, K., & Li, X. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02159-y · Cited by 13
Biochemical markers of bone turnover in osteoporosis
Szulc, P., Bauer, D. C., & Eastell, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813073-5.00065-4 · Cited by 19
Translational Strategies to Target Metastatic Bone Disease
Pagnotti, G. M., Trivedi, T., & Mohammad, K. S. (2022) · Cells · doi:10.3390/cells11081309 · Cited by 13
Insights into the Mechanism of Osteoporosis and the Available Treatment Options
Muniyasamy, R., & Manjubala, I. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010273783231027073117 · Cited by 13
Metadata
- Authors
- McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., Katz, L., Maddox, J., Yang, Y.-C., Libanati, C., & Bone, H. G.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Amgen (United States) (US)
- KU Leuven (BE)
- National Institutes of Health (US)
- Centre hospitalier universitaire de Québec (CA)
- Aarhus University Hospital (DK)
- University of Liège (BE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-30
- Volume
- 370
- Issue
- 5
- Pages
- 412-420
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096627331
- Cited by
- 1,258
- References
- 16
- Citations by year
- 2026: 75 · 2025: 97 · 2024: 82 · 2023: 52 · 2022: 99 · 2021: 93 · 2020: 121 · 2019: 69 · 2018: 90 · 2017: 105 · 2016: 125 · 2015: 139 · 2014: 101
- FWCI
- 160.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- romosozumab, sclerostin, postmenopausal osteoporosis, osteopenia, bone mineral density, bone formation, bone resorption, alendronate, teriparatide, osteocytes, osteoblast activity, monoclonal antibodies, dose comparison, injection site reactions
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Calcium, Drug Administration Schedule, Female, Humans, Injections, Subcutaneous, Lumbar Vertebrae, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Least-Squares Analysis, Bone Remodeling, Teriparatide, Alendronate, Bone Density Conservation Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.